Galectin Therapeutics Inc GALT

US Biotechnology
$3.90 β–Ό -1.52% ($-0.06)
🔥 High Short Interest
Open $3.93
Prev Close $3.96
Day Range $3.86 – $3.99
52W Range $2.03 – $7.13
Market Cap $393.31M
Beta 0.52
EPS (TTM) $-0.43

πŸ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2002-09-04
Shares Out.65,860,000
Websitegalectintherapeutics.com/ β†—
Phone16786203186
Employees9
Revenue$0
Gross Profit$0
Net Income-$9.1M
Free Cash Flow-$15.9M
Total Assets$14.8M
Total Liabilities$151.7M
Equity-$138.6M
About Galectin Therapeutics Inc

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics Inc is a publicly traded company under the ticker symbol GALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

πŸ“Š Analyst Ratings

7 analysts (2026-09-01)

Strong Buy 2
Buy 4
Hold 1

πŸ“° Latest News for GALT

πŸ‘₯ Related Stocks